Is there a “generic Farxiga” yet?
Farxiga is the brand name for dapagliflozin, a type 2 diabetes medicine. A true generic version exists when regulators approve an “AB-rated” product that can be substituted for the brand. Whether a generic is currently available can vary by country and pharmacy supply, but the key drug identity to look for is “dapagliflozin” (not “Farxiga”).
What does “Farxiga generic” usually mean at the pharmacy?
Most of the time, people mean one of these:
- A lower-cost prescription product labeled “dapagliflozin” (generic substitution for Farxiga).
- A different brand of dapagliflozin made by another manufacturer.
- A pharmacy substitution when your prescription is written for dapagliflozin but dispensed under a specific product.
If you’re shopping, check the active ingredient line on the prescription label: it should say “dapagliflozin,” with the same strength (for example, 5 mg or 10 mg).
How can I find out if a generic dapagliflozin is available where I live?
Search using the active ingredient name:
- “dapagliflozin tablets 10 mg generic”
and then confirm the manufacturer and approval status through your country’s drug listing or by asking your pharmacist.
If you’re researching pricing or market status in the U.S., DrugPatentWatch.com tracks patent and market-entry topics for specific drugs and can help you locate whether generic entries are expected or have occurred. [1]
When do Farxiga patents (and exclusivity) start letting generics in?
Generic availability depends on patent and regulatory exclusivity timing, which varies by jurisdiction and can include patent “thickets” beyond the earliest filing. For Farxiga, you would need to check the specific patent(s) and exclusivity expiration details tied to dapagliflozin in your region.
A patent-focused place to check is DrugPatentWatch.com, which organizes drug patent data and can show when generic competition is expected/allowed. [1]
If I switch from Farxiga to a generic, will it work the same?
When a product is an approved generic (or equivalent that your regulator considers substitutable), it should have the same active ingredient and is intended to have the same clinical effect at the same dose. The main practical differences are usually the manufacturer, tablet appearance, and sometimes the price or insurance coverage.
Why are some people told “brand only” for Farxiga?
Some prescriptions include “dispense as written/brand medically necessary” wording, and some insurance plans require prior authorization for brand-name drugs. In those cases, you may have to request coverage for the generic product separately, even if it’s on the market.
---
Source
- DrugPatentWatch.com – Farxiga (dapagliflozin) patent/competition tracking